Who Invented Mounjaro and How Did Tirzepatide Come to Be?

Step 1: The science that started it, why Lilly pursued a dual receptor

The foundation for who invented tirzepatide lies in decades of research into gut hormones. Scientists had known for years that GLP-1 (glucagon-like peptide-1) plays a role in appetite regulation and blood-sugar control, which is why earlier GLP-1 medicines attracted so much attention. What Lilly's researchers pursued was a more ambitious question: what if a single molecule could engage a second gut hormone receptor (GIP (glucose-dependent insulinotropic polypeptide)) at the same time?

GIP and GLP-1 work through related but distinct pathways. Both affect how the body handles food and energy; both slow gastric emptying and reduce appetite. Lilly's hypothesis was that a molecule binding to both receptors could produce a stronger and more durable effect than either pathway alone. That hypothesis eventually became tirzepatide. It is the only medicine of its kind licensed for weight management in the UK, a genuinely different mechanism, not just a refinement of what came before.

The molecular design required years of preclinical work: finding a peptide structure stable enough to survive once-weekly dosing, selective enough to activate both receptors without off-target effects, and manufacturable at scale. The patents Lilly filed through the 2010s sketch the scope of that effort, and if you are curious about when Mounjaro was invented, that page traces the timeline from early research through to approval. For a fuller look at the company behind the drug, this page covers who made Mounjaro and Eli Lilly's role in more detail.

Step 2: The SURPASS and SURMOUNT clinical programmes, tirzepatide tested at scale

Before any medicine reaches patients, it must pass through structured human trials. Tirzepatide went through two large clinical programmes: SURPASS, focused on type 2 diabetes, and SURMOUNT, focused on weight management in adults without diabetes.

SURMOUNT-1, published in the New England Journal of Medicine, enrolled 2,539 adults and ran for 72 weeks. At the 15mg dose, participants lost around 20 to 21% of their body weight on average. That figure is the one most quoted, but it was the consistency across doses (meaningful weight loss at 5mg and 10mg too) that gave regulators confidence in the dose-escalation approach. The SURPASS programme, meanwhile, demonstrated benefit across glycaemic control in type 2 diabetes, giving tirzepatide a dual licence.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, went further: it compared tirzepatide directly against semaglutide 2.4mg in a head-to-head study over 72 weeks. Tirzepatide produced greater average weight loss, though both medicines showed clinically meaningful results. If you want the detail of what the evidence shows in practice, this page addresses what to expect if progress is slower than the trials suggest.

Trials on this scale (thousands of participants, multiple dose arms, long follow-up periods) are expensive and slow. It is one reason why genuinely new weight-loss medicines appear rarely. Tirzepatide's development spanned most of a decade from early human studies to the first approvals.

Step 3: Regulatory approval and the Mounjaro brand reaches the UK

The US FDA approved tirzepatide for type 2 diabetes in May 2022, under the brand name Mounjaro. The weight-management approval in the US followed in late 2023. The UK followed a parallel but independent path through the MHRA, which licenses medicines separately from the FDA.

The MHRA granted Mounjaro a UK licence for weight management, and NICE published its technology appraisal (TA1026) in December 2024, recommending tirzepatide for NHS use in adults with BMI of 35 or above and at least one weight-related condition (with lower thresholds for some ethnic backgrounds). That recommendation set the phased NHS rollout in motion, with the first eligible cohort gaining access from June 2025. The NICE TA1026 guidance sets out the full eligibility criteria and implementation timeline.

Mounjaro carries a Black Triangle (▼) designation, meaning the MHRA requires healthcare professionals to report any suspected side effects to support ongoing monitoring. This is standard for newly approved medicines, not a signal of unusual risk. If you are looking at the UK pricing picture (Lilly revised its UK list price significantly from September 2025) this page explains what changed and why.

Step 4: Mounjaro as a licensed UK medicine today, and what that means practically

The journey from Lilly's research labs to a pre-filled KwikPen in a UK patient's fridge is the story of tirzepatide's invention playing out at a regulatory and commercial level. Today, Mounjaro is available in six UK strengths (2.5mg up to 15mg) dispensed as a once-weekly subcutaneous injection. Treatment starts at 2.5mg to help the body adjust gradually, with the prescriber guiding any increases.

Access in the UK runs through two routes. The NHS route is phased and depends on meeting strict criteria; the private route through a regulated pharmacy means no waiting list, but requires the same clinical assessment. A GPhC-registered prescriber reviews the consultation before any prescription is issued. If you are unsure whether Mounjaro is the right fit for your circumstances, this page explains who Mounjaro is suitable for and helps clarify the eligibility picture. Worth noting: Mounjaro is dispensed through the licensed UK supply chain, not manufactured differently for private patients, the medicine is identical; the route to it differs.

Interestingly, the timing of supply sometimes catches people out. The month a manufacturer adjusts production runs or the week between Christmas and new year can affect availability, something that a prescribing service with direct supplier relationships is better placed to manage than a single high-street pharmacy. If you are weighing up the broader options, this overview of weight-loss treatments sets out what is currently licensed in the UK. To understand the medicine itself in more depth, our full Mounjaro page covers mechanism, evidence and eligibility side by side. When you are ready to speak to a prescriber, start your free consultation and a GPhC-registered clinician will review your case the same day.